Truist Financial Lowers Integra LifeSciences (NASDAQ:IART) Price Target to $21.00

Integra LifeSciences (NASDAQ:IART) had its target price lowered by investment analysts at Truist Financial from $26.00 to $21.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s price target points to a potential upside of 10.53% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Bank of America decreased their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. JMP Securities decreased their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Finally, Citigroup decreased their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average price target of $26.50.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $0.23 during mid-day trading on Monday, reaching $19.00. 52,934 shares of the company’s stock were exchanged, compared to its average volume of 1,108,472. The firm has a 50-day moving average price of $19.27 and a two-hundred day moving average price of $25.98. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 0.62 and a beta of 1.09. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter in the previous year, the firm posted $0.71 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. Analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of Michigan Retirement System boosted its holdings in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after buying an additional 400 shares during the period. CWM LLC boosted its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the period. Blue Trust Inc. boosted its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in Integra LifeSciences by 1.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock valued at $1,764,000 after buying an additional 551 shares during the period. Finally, Texas Permanent School Fund Corp boosted its stake in Integra LifeSciences by 1.5% during the first quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock valued at $2,110,000 after buying an additional 870 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.